MedTrace Logo

Study of Telotristat Etiprate (LX1606) in Participants With Symptomatic Carcinoid Syndrome

NCT01104415 · Status: COMPLETED · Phase: PHASE2 · Type: INTERVENTIONAL · Enrollment: 15

Last updated 2019-03-15

Study results available
· View outcomes & findings →

Summary

The purpose of the study is to evaluate the safety and tolerability of orally administered telotristat etiprate (LX1606) in participants with symptomatic carcinoid syndrome.

Conditions

  • Carcinoid Syndrome

Interventions

DRUG

Telotristat etiprate

Telotristat etiprate capsules orally three times daily.

Sponsors & Collaborators

  • Lexicon Pharmaceuticals

    lead INDUSTRY

Principal Investigators

  • Pablo LaPuerta, MD · Lexicon Pharmaceuticals, Inc.

Study Design

Allocation
RANDOMIZED
Purpose
TREATMENT
Masking
NONE
Model
SINGLE_GROUP

Eligibility

Min Age
18 Years
Sex
ALL
Healthy Volunteers
No

Timeline & Regulatory

Start
2010-06-15
Primary Completion
2014-02-12
Completion
2014-02-12
FDA Drug
Yes

Countries

  • Germany
  • United Kingdom

Study Locations

More Related Trials

Read the full study record

This page highlights key information. For complete eligibility criteria, study locations, investigator contacts, and the full protocol, visit the original record on ClinicalTrials.gov.

View NCT01104415 on ClinicalTrials.gov